Turnstone Biologics has announced a “strategic prioritisation of its pipeline”, as well as a workforce reduction of approximately 60% and changes to its leadership team. The cuts are designed to allow the company to focus resources on the continued advancement of its Phase I programme, selected tumour-infiltrating lymphocyte (TIL) therapy TIDAL-01. “Following a comprehensive evaluation […]